AstraZeneca is trading approximately 9% down at £11,500 following reports of preliminary merger talks with Bristol Myers Squibb for a potential $400 billion tie-up.
- Shareholders have raised concerns over the strategic logic, valuation, and execution challenges associated with the proposed mega-deal.
- Significant selling pressure began on August 3, 2026, as investors view the transaction as overly complex and risky for the company's outlook.